Overview

Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer

Status:
Completed
Trial end date:
2009-12-21
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as G-CSF may increase the number of immune cells found in bone marrow or peripheral blood and may help a person 's immune system recover from the side effects of chemotherapy. PURPOSE: Phase I/II trial to study the effectiveness of docetaxel and epirubicin with and without G-CSF in treating women with metastatic breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
NCIC Clinical Trials Group
Treatments:
Docetaxel
Epirubicin